Erratum to Construction and validation of a predictive model for the risk of three-month-postoperative malnutrition in patients with gastric cancer: a retrospective case-control study
Erratum to: J Gastrointest Oncol 2023;14:128-45.
In the February 2023 issue of Journal of Gastrointestinal Oncology, the article titled “Construction and validation of a predictive model for the risk of three-month-postoperative malnutrition in patients with gastric cancer: a retrospective case-control study” authored by Dr. Dai et al. (1) was published with errors in Table 1 and Table 3.
In Table 1 and Table 3, the characteristics ‘Age’ is incorrectly categorised. The statistical analyses were based on a threshold of 65 years of age, but in the tables, 70 years of age is used as the threshold.
The corrected Table 1 and Table 3 are presented below.
Table 1
| Characteristics | Total | Non-malnutrition group, n=137 | Malnutrition group, n=105 | Z/t/χ² | P |
|---|---|---|---|---|---|
| Gender, n (%) | 0.242 | 0.623 | |||
| Male | 179 (73.97) | 103 (75.18) | 76 (72.38) | ||
| Female | 63 (26.03) | 34 (24.82) | 29 (27.62) | ||
| Age, years, n (%) | 6.618 | 0.010 | |||
| <65 | 108 (44.63) | 71 (51.82) | 37 (35.24) | ||
| ≥65 | 134 (55.37) | 66 (48.18) | 68 (64.76) | ||
| BMI, kg/m2, n (%) | 3.638 | 0.303 | |||
| <18 | 3 (1.24) | 0 (0.00) | 3 (2.86) | ||
| 18–24 | 142 (58.68) | 82 (59.85) | 60 (57.14) | ||
| 24–27.5 | 66 (27.27) | 38 (27.74) | 28 (26.67) | ||
| >27.5 | 31 (12.81) | 17 (12.41) | 14 (13.33) | ||
| MAMC, n (%) | 1.096 | 0.295 | |||
| Abnormal | 92 (38.02) | 56 (40.88) | 36 (34.29) | ||
| Normal | 150 (61.98) | 81 (59.12) | 69 (65.71) | ||
| Smoking history, n (%) | 3.057 | 0.080 | |||
| No | 133 (54.96) | 82 (59.85) | 51 (48.57) | ||
| Yes | 109 (45.04) | 55 (40.15) | 54 (51.43) | ||
| History of diabetes, n (%) | 1.066 | 0.302 | |||
| No | 194 (80.17) | 113 (82.48) | 81 (77.14) | ||
| Yes | 48 (19.83) | 24 (17.52) | 24 (22.86) | ||
| History of hypertension, n (%) | 0.000 | 0.986 | |||
| No | 173 (71.49) | 98 (71.53) | 75 (71.43) | ||
| Yes | 69 (28.51) | 39 (28.47) | 30 (28.57) | ||
| Alcohol history, n (%) | 1.088 | 0.297 | |||
| No | 143 (59.09) | 77 (56.20) | 66 (62.86) | ||
| Yes | 99 (40.91) | 60 (43.80) | 39 (37.14) | ||
| Pulmonary function grading, n (%) | 1.723 | 0.632 | |||
| 1 | 96 (39.67) | 55 (40.15) | 41 (39.05) | ||
| 2 | 104 (42.98) | 60 (43.80) | 44 (41.90) | ||
| 3 | 38 (15.70) | 21 (15.33) | 17 (16.19) | ||
| 4 | 4 (1.65%) | 1 (0.73) | 3 (2.86) | ||
| Cardiac function grading, n (%) | 6.931 | 0.031 | |||
| Normal | 144 (59.50) | 91 (66.42) | 53 (50.48) | ||
| Diastolic HF | 73 (30.17) | 36 (26.28) | 37 (35.24) | ||
| Systolic HF | 25 (10.33) | 10 (7.30) | 15 (14.28) | ||
| Pain grading on admission, n (%) | 7.029 | 0.071 | |||
| 0 | 149 (61.57) | 92 (67.15) | 57 (54.29) | ||
| 1 | 52 (21.49) | 28 (20.44) | 24 (22.86) | ||
| 2 | 27 (11.16) | 13 (9.49) | 14 (13.33) | ||
| 3 | 14 (5.79) | 4 (2.92) | 10 (9.52) | ||
| Grading of self-care ability on admission, n (%) | 1.084 | 0.781 | |||
| 0 | 92 (38.02) | 52 (37.96) | 42 (40.00) | ||
| 1 | 103 (42.56) | 59 (43.07) | 44 (41.90) | ||
| 2 | 32 (13.22) | 17 (12.41) | 15 (14.29) | ||
| 3 | 13 (5.37) | 9 (6.57) | 4 (3.81) | ||
| Neoadjuvant, n (%) | 0.063 | 0.969 | |||
| No | 168 (69.42) | 96 (70.07) | 72 (68.57) | ||
| Yes | 74 (30.58) | 41 (29.93) | 33 (31.43) | ||
| Surgical method, n (%) | |||||
| LAG | 180 (74.38) | 104 (78.10) | 76 (72.38) | 1.055 | 0.304 |
| TLG | 62 (25.62) | 30 (21.90) | 29 (27.62) | ||
| Surgical scope, n (%) | 2.064 | 0.356 | |||
| LTG | 146 (60.33) | 78 (56.90) | 68 (64.76) | ||
| LPG | 37 (15.29) | 21 (15.33) | 16 (15.24) | ||
| LDG | 59 (24.38) | 38 (27.77) | 21 (20.00) | ||
| TNM stage, n (%) | 19.578 | <0.001 | |||
| I | 68 (28.10) | 50 (36.49) | 18 (17.15) | ||
| II | 106 (43.80) | 62(45.26) | 44 (41.90) | ||
| III | 68 (28.10) | 25 (18.25) | 43 (40.95) | ||
| Degree of differentiation, n (%) | 2.777 | 0.249 | |||
| Good differentiation | 98 (40.50) | 50 (36.50) | 48 (45.71) | ||
| Moderate differentiation | 111 (45.87) | 65 (47.45) | 46 (43.81) | ||
| Poor differentiation | 33 (13.64) | 22 (16.06) | 11 (10.48) | ||
| C-reactive protein, M [P25, P75] | 5.75 [3.30, 11.97] | 5.50 [3.30, 10.30] | 5.90 [3.50, 17.60] | 0.056 | 0.056 |
| Glycosylated hemoglobin, M [P25, P75] | 5.50 [4.90, 6.10] | 5.60 [4.90, 6.10] | 5.50 [4.90, 5.80] | −0.853 | 0.394 |
| Carcinoembryonic antigen, M [P25, P75] | 3.29 [1.61, 6.72] | 2.91 [1.53, 5.66] | 3.77 [1.89, 13.26] | −2.775 | 0.006 |
| Alb, M [P25, P75] | 37.15 [33.00, 39.90] | 38.30 [34.70, 40.70] | 35.40 [31.10, 38.10] | −4.579 | <0.001 |
| PAB, M [P25, P75] | 220.00 [176.50, 263.00] | 245.00 [205.00, 279.00] | 186.00 [157.00, 214.00] | −7.657 | <0.001 |
| Triglycerides, M [P25, P75] | 1.26 [0.94, 1.63] | 1.31 [0.99, 1.72] | 1.18 [0.88, 1.54] | −2.172 | 0.033 |
| ALT, M [P25, P75] | 18.00 [12.00, 28.00] | 19.00 [13.00, 28.00] | 17.00 [11.00, 27.00] | −1.268 | 0.205 |
| AST, M [P25, P75] | 21.00 [17.00, 31.00] | 20.00 [16.00, 30.00] | 24.00 [18.00, 32.00] | −1.934 | 0.053 |
| Creatinine, M [P25, P75] | 65.00 [53.00, 78.00] | 64.00 [55.00, 76.00] | 65.00 [51.00, 81.00] | −0.200 | 0.841 |
| Urea nitrogen, M [P25, P75] | 5.54 [4.52, 6.91] | 5.57 [4.70, 6.82] | 5.42 [4.12, 7.45] | −0.809 | 0.419 |
| Serum sodium, M [P25, P75] | 140.90 [139.40, 143.07] | 141.30 [139.70, 143.00] | 140.50 [138.90, 143.20] | −1.825 | 0.068 |
| Serum potassium, M [P25, P75] | 4.02 [3.72, 4.32] | 4.01 [3.73, 4.30] | 4.05 [3.70, 4.34] | −0.525 | 0.599 |
| Hemoglobin, M [P25, P75] | 108.00 [82.25, 130.00] | 113.00 [87.00, 132.00] | 103.00 [73.00, 127.00] | −2.400 | 0.016 |
| NLR, M [P25, P75] | 2.54 [1.77, 4.21] | 2.48 [1.58, 3.58] | 2.92 [1.92, 5.39] | −2.680 | 0.007 |
| Adjuvant chemotherapy, n (%) | 1.990 | 0.738 | |||
| No | 23 (9.50) | 15 (10.95) | 8 (7.62) | ||
| Incomplete | 53 (21.90) | 33 (24.09) | 20 (19.05) | ||
| Complete | 166 (68.88) | 89 (64.96) | 77 (74.04) | ||
| Postoperative complications, n (%) | 1.220 | 0.269 | |||
| No | 210 (86.78) | 116 (84.67) | 94 (89.52) | ||
| Yes | 32 (13.22) | 21 (15.33%) | 11 (10.48) | ||
| EN within Post-op 48h, n (%) | 3.721 | 0.054 | |||
| Yes | 169 (69.83) | 103 (75.18) | 66 (62.86) | ||
| No | 73 (30.17) | 34 (24.82) | 39 (37.14) | ||
BMI, body mass index; MAMC, mid-arm muscle circumference; HF, heart failure; LAG, laparoscopic assisted radical gastrectomy; TLG, total laparoscopic radical gastrectomy; LTG, laparoscopic total gastrectomy; LPG, laparoscopic proximal gastrectomy; LDG, laparoscopic distal gastrectomy; TNM, Tumor node metastasis; Alb, albumin; PAB, prealbumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; NLR, neutrophil-to-lymphocyte ratio; EN, enteral nutrition; Post-op, postoperative.
Table 3
| Characteristics | Training set, n=242 | Validation set, n=102 | Z/t/χ² | P |
|---|---|---|---|---|
| Gender, n (%) | 1.425 | 0.233 | ||
| Male | 179 (73.97) | 69 (67.65) | ||
| Female | 63 (26.03) | 33(32.35) | ||
| Age, years, n (%) | 0.171 | 0.679 | ||
| <65 | 108 (44.63) | 48 (47.06) | ||
| ≥65 | 134 (55.37) | 54 (52.94) | ||
| BMI, kg/m2, n (%) | 4.179 | 0.243 | ||
| <18 | 3 (1.24) | 3 (2.94) | ||
| 18–24 | 142 (58.68) | 50 (49.02) | ||
| 24–27.5 | 66 (27.27) | 30 (29.41) | ||
| >27.5 | 31 (12.81) | 19 (18.63) | ||
| MAMC, n (%) | 3.584 | 0.058 | ||
| Abnormal | 92 (38.02) | 50 (49.02) | ||
| Normal | 150 (61.98) | 52 (50.98) | ||
| Smoking history, n (%) | 0.709 | 0.400 | ||
| No | 133 (54.96) | 51 (50) | ||
| Yes | 109 (45.04) | 51 (50) | ||
| History of diabetes, n (%) | 1.853 | 0.173 | ||
| No | 194 (80.17) | 75 (73.53) | ||
| Yes | 48 (19.83) | 27 (26.47) | ||
| History of hypertension, n (%) | 1.778 | 0.182 | ||
| No | 173 (71.49) | 80 (78.43) | ||
| Yes | 69 (28.51) | 22 (21.57) | ||
| Alcohol history, n (%) | 0.949 | 0.330 | ||
| No | 143 (59.09) | 66 (64.71) | ||
| Yes | 99 (40.91) | 36 (35.29) | ||
| Pulmonary function grading, n (%) | 6.683 | 0.083 | ||
| 1 | 96 (39.67) | 45 (44.12) | ||
| 2 | 104 (42.98) | 41 (40.2) | ||
| 3 | 38 (15.7) | 10 (9.8) | ||
| 4 | 4 (1.65) | 6 (5.88) | ||
| Cardiac function grading, n (%) | 0.239 | 0.887 | ||
| Normal | 144 (59.50) | 63 (61.76) | ||
| Diastolic HF | 73 (30.17) | 30 (29.41) | ||
| Systolic HF | 25 (10.33) | 9 (8.83) | ||
| TNM stage, n (%) | 0.249 | 0.883 | ||
| I | 68 (28.10) | 30 (29.41) | ||
| II | 106 (43.80) | 46 (45.10) | ||
| III | 68 (28.10) | 26 (25.49) | ||
| Pain grading on admission, n (%) | 1.198 | 0.754 | ||
| 0 | 149 (61.57) | 61 (59.8) | ||
| 1 | 52 (21.49) | 19 (18.63) | ||
| 2 | 27 (11.16) | 15 (14.71) | ||
| 3 | 14 (5.79) | 7 (6.86) | ||
| Grading of NRS on admission, n (%) | 2.037 | 0.153 | ||
| <3 | 184 (76.03) | 70 (68.63) | ||
| ≥3 | 58 (23.97) | 32 (31.37) | ||
| Grading of self-care ability on admission, n (%) | 2.750 | 0.432 | ||
| 0 | 92 (38.02) | 45 (44.12) | ||
| 1 | 103 (42.56) | 42 (41.18) | ||
| 2 | 32 (13.22) | 8 (7.84) | ||
| 3 | 13 (5.37) | 7 (6.86) | ||
| Alb, M [P25, P75] | 37.15 [33.00, 39.90] | 37.20 [34.65, 39.50] | 0.490 | 0.624 |
| Prealbumin, M [P25, P75] | 220.00 [176.50, 263.00] | 225.50 [183.00, 266.00] | 0.747 | 0.455 |
| Neutrophils/lymphoc, M [P25, P75] | 2.55[1.76, 4.23] | 2.63 [1.67, 4.35] | 0.177 | 0.860 |
| Neoadjuvant, n (%) | 0.046 | 0.830 | ||
| No | 168 (69.42) | 72 (70.59) | ||
| Yes | 74 (30.58) | 30 (29.41) | ||
| Surgical method, n (%) | 0.047 | 0.829 | ||
| LAG | 160 (66.12) | 70 (68.63) | ||
| TLG | 82 (33.88) | 32 (31.37) | ||
| Surgical scope, n (%) | 0.055 | 0.973 | ||
| LTG | 135 (55.79) | 61 (59.80) | ||
| LPG | 37 (15.29) | 15 (14.71) | ||
| LDG | 70 (28.93) | 26 (25.49) | ||
| Adjuvant chemotherapy, n (%) | 0.241 | 0.883 | ||
| Good differentiation | 98 (40.50) | 43 (40.50) | ||
| Moderate differentiation | 111 (45.87) | 47 (44.76) | ||
| Poor differentiation | 33 (13.64) | 12 (11.76) | ||
| Postoperative complications, n (%) | 3.776 | 0.052 | ||
| No | 210 (86.78) | 80 (78.43) | ||
| Yes | 32 (13.22) | 22 (21.57) | ||
| EN within 48h post-op, n (%) | 0.002 | 0.967 | ||
| Yes | 169 (69.83) | 71 (69.61) | ||
| No | 73 (30.17) | 31 (30.39) | ||
BMI, body mass index; MAMC, mid-arm muscle circumference; HF, heart failure; TNM, tumor node metastasis; NRS2002, nutritional risk screening 2002; Alb, albumin; LAG, laparoscopic assisted radical gastrectomy; TLG, total laparoscopic radical gastrectomy; LTG, laparoscopic total gastrectomy; LPG, laparoscopic proximal gastrectomy; LDG, laparoscopic distal gastrectomy; EN, enteral nutrition; Post-op, postoperative.
The authors apologize for these errors and state that these errors do not change the scientific conclusions of the article in any way.
Click here to view the updated version of the article.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
- Dai T, Wu D, Tang J, et al. Construction and validation of a predictive model for the risk of three-month-postoperative malnutrition in patients with gastric cancer: a retrospective case-control study. J Gastrointest Oncol 2023;14:128-45. [Crossref] [PubMed]
